Evidence map›Paper›PMID 38345720›Full record

ArticlePituitary2024

Elevated risk of recurrence and retreatment for silent pituitary adenomas.

Saksham Gupta, Samantha E Hoffman, Neel H Mehta, Blake Hauser, Marcelle Altshuler, Joshua D Bernstock, Timothy R Smith, Omar Arnaout, Edward R Laws

Open access · greenAbstract read
In one paragraph

Article in Pituitary, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 citations in OpenAlex.

  1. Comprehensive evaluation and analysis of pituitary hormones in male patients with non-functional pituitary adenoma during the perioperative period.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Saksham GuptaDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. sgupta@bwh.harvard.edu.
Samantha E HoffmanDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Neel H MehtaDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Blake HauserDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Marcelle AltshulerDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Joshua D BernstockDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Timothy R SmithDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Omar ArnaoutDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Edward R LawsDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Brigham and Women's Hospital · USHarvard University · US

Funding

Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

purposePituitary adenomas are the most common tumor of the pituitary gland and comprise nearly 15% of all intracranial masses. These tumors are stratified into functional or silent categories based on their pattern of hormone expression and secretion. Preliminary evidence supports differential clinical outcomes between some functional pituitary adenoma (FPA) subtypes and silent pituitary adenoma (SPA) subtypes.

methodsWe collected and analyzed the medical records of all patients undergoing resection of SPAs or FPAs from a single high-volume neurosurgeon between 2007 and 2018 at Brigham and Women's Hospital. Descriptive statistics and the Mantel-Cox log-rank test were used to identify differences in outcomes between these cohorts, and multivariate logistic regression was used to identify predictors of radiographic recurrence for SPAs.

resultsOur cohort included 88 SPAs and 200 FPAs. The majority of patients in both cohorts were female (48.9% of SPAs and 63.5% of FPAs). SPAs were larger in median diameter than FPAs (2.1 cm vs. 1.2 cm, p < 0.001). The most frequent subtypes of SPA were gonadotrophs (55.7%) and corticotrophs (30.7%). Gross total resection (GTR) was achieved in 70.1% of SPA resections and 86.0% of FPA resections (p < 0.001). SPAs had a higher likelihood of recurring (hazard ratio [HR] 3.2, 95% confidence interval [95%CI] 1.6-7.2) and a higher likelihood of requiring retreatment for recurrence (HR 2.5; 95%CI 1.0-6.1). Subset analyses revealed that recurrence and retreatment were more both likely for subtotally resected SPAs than subtotally resected FPAs, but this pattern was not observed in SPAs and FPAs after GTR. Among SPAs, recurrence was associated with STR (odds ratio [OR] 9.3; 95%CI 1.4-64.0) and younger age (OR 0.92 per year; 95%CI 0.88-0.98) in multivariable analysis. Of SPAs that recurred, 12 of 19 (63.2%) were retreated with repeat surgery (n = 11) or radiosurgery (n = 1), while the remainder were observed (n = 7).There were similar rates of recurrence across different SPA subtypes.

conclusionPatients undergoing resection of SPAs should be closely monitored for disease recurrence through more frequent clinical follow-up and diagnostic imaging than other adenomas, particularly among patients with STR and younger patients. Several patients can be observed after radiographic recurrence, and the decision to retreat should be individualized. Longitudinal clinical follow-up of SPAs, including an assessment of symptoms, endocrine function, and imaging remains critical.

Indexed as

AdenomaPituitary NeoplasmsFemaleHumansMaleNeoplasm Recurrence, LocalRetreatmentRetrospective StudiesTreatment OutcomePersonalized medicinePituitary adenomasRecurrenceSilent adenomas

Identifiers

PMID38345720
PMCPMC11014773
OpenAlexW4391747032

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.